Otsuka Pharmaceutical Co. Ltd. announced plans to acquire Mindset Pharma Inc. for C$80 million (US$50.76 million) in an all-cash deal that will see Otsuka strengthen its neurology and psychiatric pipeline. Mindset, of Toronto, is developing next-generation psychedelic therapeutics to treat psychiatric and neurological disorders with high unmet needs. Read More
As a pioneer of harnessing artificial intelligence (AI) to drug discovery, Insilico Medicine Inc. recently made breakaway progress to bring a generative AI-designed drug to life, announcing the progression of its INS018-055 candidate to phase II trials for idiopathic pulmonary fibrosis. Read More
Genexine Co. Ltd.’s recombinant human growth hormone eftansomatropin alfa (GX-H9/TJ-101) met the primary endpoint in a phase III pediatric study conducted in China in children with growth hormone deficiency, and the company plans to file a BLA in 2024 in China on the data. Read More
Blood cancer drug venetoclax could potentially be used to deplete HIV latently infected cells and delay viral rebound, leading to a potential cure for HIV, according to a study from researchers in Australia who tested the drug in humanized mice models. Read More
Data-driven health care platform company Kakao Healthcare Corp. may be embarking on its most ambitious project yet: launching an effective “AI-platform bridge” over patient waters to connect medical institutions, government and the industry for novel drug discovery and research. Read More
Rapidly evolving artificial intelligence (AI) is effectively resetting all biopharmaceutical companies to the figurative starting line, and collaboration is a key strategy to winning the drug discovery race, an AI-based startup founder said at the Global Bio Conference (GBC) 2023. Read More
Biopharma grants are up nearly 150% compared to the same time period last year, largely due to a number of $100 million-plus grants from the Biomedical Advanced Research and Development Authority (BARDA). Meanwhile, nonprofit deal value has declined year-over-year, with the number of transactions down 42.21%. Read More
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Akeso, Bristol Myers Squibb, Daiichi Sankyo, Genexine, Lianbio, Recce, Sirnaomics. Read More
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Adagene, ADC, Daiichi Sankyo, Deargen, Ena Respiratory, FBD Biologics, Hanchorbio, Henlius, Ono, Recce, Serengen, Sinovac, Twist. Read More
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Asieris, Astrazeneca, Daiichi Sankyo, Harbour, Hutchmed, Menarini, Oncomatryx. Read More
